PET imaging of neuroinflammation in treatment resistant major depressive disorder - TRD-inflammation

niversitair Medisch Centrum Groningen0 个研究点目标入组 60 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•- Age above 18 and below 50 years
•- Written informed consent for participation
•- Diagnosis of MDD as ascertained by structured Clinical Interview for DSM-IV (SCID-I) or MiniScan.
•- HDRS-17 >20
•- High level of treatment resistance/refractoriness (Ruhe et al. 2012) as defined by non-response (<50% decrease in symptoms) after >3 classes of antidepressants, given for at least 4 weeks at at least minimal effective dosages. The last antidepressant may be continued during the study.;Healthy controls
•- Age above 18 and below 50 years
•- Written informed consent for participation

•- The use of benzodiazepines within 1 week prior to the PET-scan (benzodiazepines with half-lives >24hrs must be stopped >5 times this half live before the PET-scan).
•- The use of anticoagulants or having coagulation disorder.
•- Use of somatic medication that may affect the immune system (e.g. corticoids, anti-inflammatory drugs, immune suppressive drugs)
•- Use of any investigational drug
•- Current or recent (<1 year) alcohol or substance abuse
•- Current or recent (<4 weeks) infectious or inflammatory disease
•- Current systemic disease
•- Somatic, organic or neurological disorder
•- Claustrophobia
•- Presence of materials in the body that can be magnetized, like a pacemaker, metal fragments, shunts, artificial heart valves, vascular clips, fixed hearing aid, tattoos containing metal, hair implants and artificial dentures.;Healty controls
•Identical to patients plus:
•- Personal history of (lifetime) psychiatric disorders
•- Major metabolic disease (diabetes, hyper- or hypothyroidism, Cushing disease or Addison disease)

发起方